SPR741

SPR741 is a cationic peptide derived from polymyxin B and functions as an antibiotic potentiator. It increases the permeability of the outer membrane of Gram-negative bacteria, thereby enhancing the penetration and efficacy of coadministered antibiotics against multidrug-resistant (MDR) Gram-negative pathogens. Unlike polymyxin B, SPR741 has minimal intrinsic antibacterial activity and demonstrates reduced nephrotoxicity in preclinical studies. It is primarily being developed for use in combination with other antibiotics to treat severe infections caused by resistant Gram-negative bacteria. The drug was initially developed by Northern Antibiotics Oy and further advanced by Spero Therapeutics[1][2][3][6][7].

Other names

SPR741SPR-741SPR 741NAB741NAB-741NAB 741